Studies reveal that as people age, their skin progressively becomes less hydrated and weaker, along with turning less stretchy, resulting in the formation of wrinkles. It is reported that most individuals develop wrinkles between the ages of 40 and 50 due to loss of moisture and thickness of the skin. With the expanding aging population (60 years and older), expected to reach 2.1 billion by 2050, the demand for drugs that can prevent and treat wrinkles is likely to grow significantly.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing wrinkles pipeline development activities.
Prescription creams and serums such as retinoids are commonly recommended for wrinkles treatment. Botulinum toxin injections, which temporarily relax muscles, are also used to reduce wrinkles. Injections of fillers such as hyaluronic acid are increasingly to plump up the skin and address wrinkles. With the increasing awareness of skin health and the growing demand for long-lasting and permanent anti-aging solutions, the drug pipeline for wrinkles is poised to expand in the coming years.
Biological: KB301
Description 2: Krystal Biotech, Inc., a gene therapy biotechnology company, is conducting a Phase 3 clinical trial of a replication-incompetent, non-integrating vector expressing human type III collagen (COL3), named KB301, to treat superficial skin depressions. The study has enrolled around 85 patients and is expected to be completed by May 2029.
This product will be delivered within 3-5 business days.
Report Coverage
The Wrinkles Drug Pipeline Report by the publisher gives comprehensive insights into drugs currently undergoing wrinkles clinical trials. It covers various aspects related to the details of each of these wrinkles drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The wrinkles pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from wrinkles.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing wrinkles pipeline development activities.
Wrinkles Drug Pipeline Outlook
Wrinkles refer to a natural part of aging that causes the formation of creases, folds, or ridges in the skin. Sun exposure, smoking, and genetics, among others, also result in the development of wrinkles. These folds or furrows fall into categories: dynamic and static. Dynamic wrinkles occur due to repeated facial movements whereas static wrinkles are caused by loss of elasticity of the skin.Prescription creams and serums such as retinoids are commonly recommended for wrinkles treatment. Botulinum toxin injections, which temporarily relax muscles, are also used to reduce wrinkles. Injections of fillers such as hyaluronic acid are increasingly to plump up the skin and address wrinkles. With the increasing awareness of skin health and the growing demand for long-lasting and permanent anti-aging solutions, the drug pipeline for wrinkles is poised to expand in the coming years.
Wrinkles - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of wrinkles drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The wrinkles therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Polymer
- Small Molecule
- Gene Therapy
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Wrinkles - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total clinical trials for wrinkles.Wrinkles - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under wrinkles pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for wrinkles.Wrinkles Clinical Trials Therapeutic Assessment - Competitive Dynamics
The wrinkles drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in wrinkles clinical trials:- AbbVie
- Stemedica Cell Technologies, Inc.
- AcusMu Medtech Co., Ltd.
- BTL Industries Ltd.
- GCS Co., Ltd.
- Lumenis Be Ltd.
- Integrative Skin Science and Research
- Candela Corporation
- Krystal Biotech, Inc.
- Cynosure, Inc.
Wrinkles - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for wrinkles. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of wrinkles drug candidates.Drug: BOTOX
Description 1: Sponsored by AbbVie, this prospective, multi-center, open-label clinical study aims to examine patient natural outcomes and satisfaction post administration of BOTOX® (Botulinum Toxin Type A) purified neurotoxin complex. The Phase IV trial has enrolled an estimated 100 participants with upper facial lines (forehead lines, glabellar lines, and lateral canthal lines).Biological: KB301
Description 2: Krystal Biotech, Inc., a gene therapy biotechnology company, is conducting a Phase 3 clinical trial of a replication-incompetent, non-integrating vector expressing human type III collagen (COL3), named KB301, to treat superficial skin depressions. The study has enrolled around 85 patients and is expected to be completed by May 2029.
Reasons To Buy This Report
The Wrinkles Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for wrinkles. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into wrinkles collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.Key Questions Answered in the Wrinkles - Pipeline Insight Report
- Which companies/institutions are leading the wrinkles drug development?
- What is the efficacy and safety profile of wrinkles pipeline drugs?
- Which company is leading the wrinkles pipeline development activities?
- What is the current wrinkles commercial assessment?
- What are the opportunities and challenges present in the wrinkles drug pipeline landscape?
- What is the efficacy and safety profile of wrinkles pipeline drugs?
- Which company is conducting major trials for wrinkles drugs?
- Which companies/institutions are involved in wrinkles collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in wrinkles?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Wrinkles
4 Patient Profile: Wrinkles Pipeline
5 Wrinkles: Epidemiology Snapshot
6 Wrinkles: Market Dynamics
7 Wrinkles: Key Facts Covered
8 Wrinkles, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Wrinkles Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Wrinkles Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Wrinkles Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Wrinkles Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Wrinkles, Key Drug Pipeline Companies
